US OptionsDetailed Quotes

COGT241220P19000

Watchlist

0.00
0.000.00%

15min DelayClose Nov 27 09:30 ET

0.00High0.00Low

Cogent Biosciences Stock Discussion

Trytosaveabit

Jun 14 06:37

Update

$Cogent Biosciences (COGT.US)$ Reuters· 3 mins ago
Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions

Trytosaveabit

May 23 17:03

Even better!

$Cogent Biosciences (COGT.US)$ Cogent Biosciences (COGT) said Thursday that new lead-in data from ongoing phase 3 trial of a combination of bezuclastinib and sunitinib showed potential to become new standard of care for advanced gastrointestinal stromal tumors, a type of cancer.
The company said the combination treatment led to a disease control rate of 80% in all patients and 100% in patients that were previously treated with imatinib only.
"Coupled with the impressive clinical activ...

Trytosaveabit

May 23 16:12

Update

$Cogent Biosciences (COGT.US)$ Cogent Biosciences Reports Updated Lead-In Data From Ongoing Phase 3 PEAK Trial At ASCO Annual Meeting
Addition of Bezuclastinib to Sunitinib Continues to Be Generally Well-Tolerated With an Encouraging Safety Profile

Stock Region

Feb 23 10:35

Positive 1b Data For Mastocytosis Therapy Announced By Major Biotech Company

Cogent Biosciences Unveils Positive Data from SUMMIT Trial of Bezuclastinib in Nonadvanced Systemic Mastocytosis Patients.
In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data from its SUMMIT trial evaluating Bezuclastinib, a novel targeted therapy, in patients with nonadvanced systemic mastocytosis (SM). The news marks a major milestone in the ongoing efforts to d...

Trytosaveabit

Feb 22 14:01

Sorry a bit late! Grrrr! Was busy! Grrrr

$Cogent Biosciences (COGT.US)$ Cogent Biosciences Announces Positive Part 1b Data From SUMMIT Trial Evaluating Bezuclastinib in Patients With Nonadvanced Systemic Mastocytosis
GlobeNewswire· 30 mins ago

JuliaBiswas

Feb 22 01:49

$Cogent Biosciences (COGT.US)$ new data is comin for mastocytosis, the presentation is scheduled at AAAAI conference in a couple of days. And bezuclastinib soon will be a new standard of care for GIST.